Navigation Links
NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:4/1/2009

e or update publicly any forward-looking statement except as required by law. 



    Contact:

    NovaBay Pharmaceuticals, Inc.
    Tom Paulson, 510-899-8809
    Chief Financial Officer
    tpaulson@novabaypharma.com

    Invigorate Communications
    Investor Relations:
    Gregory Gin, 908-376-7737
    ggin@invigoratepr.com

    Media Relations:
    Mariesa Kemble, 608-850-4745
    mkemble@invigoratepr.com



                            NOVABAY PHARMACEUTICALS, INC
                       (formerly NovaCal Pharmaceuticals Inc.)
                           (a developmental stage company)
                             CONSOLIDATED BALANCE SHEETS
                        (in thousands, except per share data)


                                                   December 31, December 31,
                                                        2007         2008

    ASSETS
       Current assets:
          Cash and cash equivalents                    $10,941      $12,099
          Short-term investments                        11,412            -
          Prepaid expenses and other current assets        419          414
          Total current assets                          22,772       12,513
       Property and equipment, net                       1,150        1,456
       TOTAL ASSETS                                    $23,922      $13,969

    LIABILITIES AND STOCKHOLDERS' EQUITY
    Liabilities:
       Current liabilities:
          Accounts payable                                $142         $406
          Accrued liabilities                            1,141        1,166
          Capital lease obligation                          37           42
          Equipment loan                                   219          366
          Deferred revenue                           
'/>"/>
SOURCE  NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 

Related biology technology :

1. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
2. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
3. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
6. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
10. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... PHILADELPHIA, Dec. 15 The Center ... Advanstar Communications, is pleased to announce the ... Pharmaceutical/Biotech Accounting and Reporting Congress . The ... Philadelphia, on March 16-17, 2010. ,, Over ... professionals have attended this premier event since ...
(Date:12/14/2009)... OAKS, Calif., Dec. 14 Array BioPharma ... AMGN ) today announced that they entered ... to Array,s small-molecule glucokinase activator program, including ARRY-403, ... trial in patients with Type 2 diabetes. ... Array will receive an upfront payment of $60 ...
(Date:12/14/2009)... Corporation (NYSE: BSX ) today announced the ... principal amount of its senior notes under the Company,s ... $850 million of 4.50 percent notes due January 2015, ... and $300 million of 7.375 percent notes due January ... proceeds for general corporate purposes, including prepaying its bank ...
(Date:12/14/2009)... , - Results From ... Rheumatoid Arthritis in Seven Major Industrialized Countries , , ... arthritis say their disease, impacts ... Women living with rheumatoid arthritis find shopping for gifts, ... wrapping presents most, difficult to ...
Breaking Biology Technology:CBI Announces the Agenda for Their 6th Annual Pharmaceutical/Biotech Accounting and Reporting Congress 2Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4
... with substantially increased capacity, for continued ... announced today robust double digit growth in sales, improved ... quarter ended March 31, 2009. , In a news ... "Our 43% growth in the first half of 2009 ...
... 14 Nucletron, a,knowledge-based leader in radiation ... Brachy, a comprehensive film- and volume-based treatment,planning ... brachytherapy.,Oncentra Brachy, the world,s first fully DICOM-compatible ... system that features,state-of-the-art optimization algorithms to ensure ...
... May 14 Experts from PAREXEL Consulting will present ... Convention, to be held May 18-21, 2009 at the ... is a business unit of PAREXEL International (Nasdaq: ... biopharmaceutical and medical device industries. PAREXEL Consulting experts will ...
Other Biology Technology:Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 2Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 3Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 4Nucletron Releases Comprehensive Film-and Volume-Based Planning System for Wide Variety of Brachy Solutions 2PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 2PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 3PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention 4
(Date:12/15/2009)... 2006, a team of Spanish and American researchers found the ... Bonares, Huelva. Now they have published, for the first time, ... with the death of the young cetacean, possibly a baleen ... first discovery of the partial fossil remains of a whale ... Huelva Sands sedimentary formation, but it is the first time ...
(Date:12/15/2009)... HERNDON, Va., Dec. 15 The PTR Group, ... today announced that it has agreed to sponsor three ... US FIRST Robotics Competition ( http://usfirst.org ). ... high school teams in three different states. The ... in Rockwall, TX, and James Madison HS in Vienna, ...
(Date:12/14/2009)... or for Tasmanian devils biting each other ... the dinosaurs to extinction through the transmission of a ... Biology, highlights the ,paleobiological detective work, of David Varricchio ... to deduce that a protozoan parasite was to blame ... fossils. , The parasite,s modern-day equivalent, which infects birds, ...
Breaking Biology News(10 mins):Story of 4.5 million-year-old whale unveiled in Huelva 2Story of 4.5 million-year-old whale unveiled in Huelva 3The PTR Group Announces Financial and Technical Support to US FIRST Robotics Competition Teams 2Robert Allard Law Firm of Corsiglia McMahon 26amp 3B Allard Named 2009 Trial Lawyer of the Year 62919 1Robert Allard Law Firm of Corsiglia McMahon 26amp 3B Allard Named 2009 Trial Lawyer of the Year 62919 2World Renowned Vascular Surgeon to Conduct Training at Harvard Medical School Site on Non Invasive Treatment of Veins 62914 1World Renowned Vascular Surgeon to Conduct Training at Harvard Medical School Site on Non Invasive Treatment of Veins 62914 2World Renowned Vascular Surgeon to Conduct Training at Harvard Medical School Site on Non Invasive Treatment of Veins 62914 3New antioxidant compounds have been identified in foods such as olive oil honey and nuts 15110 1New antioxidant compounds have been identified in foods such as olive oil honey and nuts 15110 2
... , Researchers from the Department of Legal ... of Granada ( UGR ) developed a new method ... workers. Continuous exposure to certain elements constitutes one of ... Technologies for Industrial Waste Treatment (Tecnologas para el tratamiento ...
... developing the scientists of the future was at front ... in Science, Mathematics and Engineering Mentoring (PAESMEM), a program ... winners of the 2006 competition -- comprising 10 individuals ... disciplines -- were announced at the White House on ...
... Rice University,s Baker Institute for Public Policy finds that the ... even if areas that are currently restricted are opened up ... in the United States, representing 22 percent of total primary ... was imported, the vast majority from Canada. Liquefied natural gas ...
Other Biology News:Scientists develop a fast system to detect metal concentrations in iron and steel industry workers 2President honors mentors of scientists and engineers 2President honors mentors of scientists and engineers 3President honors mentors of scientists and engineers 4President honors mentors of scientists and engineers 5President honors mentors of scientists and engineers 6President honors mentors of scientists and engineers 7Baker Institute finds increased domestic production won't make US self-sufficient in natural gas 2Baker Institute finds increased domestic production won't make US self-sufficient in natural gas 3
... 100 slides. Immunocytochemistry.Sample types: suitable for ... labeling.Recommended cell number: 10 6-107 ... at 2-8 C (except DAB: -15 ... & Cellular Assays, Assays . Specific ...
... Ideal for isolation and affinity ... proteins and peptides. Hydrophobic, monodisperse magnetic ... p-toluene-sulfonyl (tosyl) groups, further surface activation ... of antibodies with optimal orientation for ...
... MPM-2, agarose conjugate Formulation: ... azide Quality Assurance: ... mitotic MPM2 antigens from ... cells as shown by ...
Calcium Channel alpha 2 delta-2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone 42, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: